Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Schedule an appointment today
Call to Schedule: 1-866-UH4-CARE
Find Clinical Trials & Studies
Visit the Research & Education Institute

Alleviatiating Congential Sucrase-Isomalatase Deficiency Symptoms Study

Back to Search Results
Share
Facebook
X
Pinterest
LinkedIn
Email
Print
I'm Interested!
Fill out our online form

Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects with Low, Moderate, and Normal Sucrase Levels

  • Sex at Birth: Any
  • Age: Child (Birth - 17)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase IV
  • Conditions Being Studied: Sucrase

Study Purpose

The purpose of this study is to investigate the effects of Sucraid® (sacrosidase) Oral Solution 8500 IU/mL treatment on gastrointestinal symptoms in subjects with low, moderate, and normal disaccharidase assay sucrase levels from an esophagogastroduodenoscopy (EGD). This study aims to explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, moderate, and normal).

Who Can Participate

Age: 6 months - 17

Principal Investigator
Thomas Sferra MD
Department/Division
Pediatrics (Gastroenterology)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions
  • UH IRB: SITE00001773
  • StudyID: 2022-0988
  • ClinicalTrials.gov: NCT05480761
I'm Interested!
Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422